LOS ANGELES--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC) today announced that the American Heart Association (AHA) has selected the company’s Myoblast Phase I(b) trial as a featured late breaking trial for its annual Scientific Sessions Conference in Orlando Florida on November 4, 2007 through November 7, 2007. The AHA’s Scientific Sessions Conference is among the premier cardiovascular research and instructional meetings worldwide bringing together interventional cardiologists, electrophysiologists, and nurses and other professionals with content from the forefront of research and clinical practice, including more than 4,000 abstracts of original research and a variety of invited programs. In addition, an International Congress on Stem Cells and Myocardial Regeneration will run concurrently with Scientific Sessions, featuring the most internationally renowned investigators in the field.
